| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC11479 | BLU-667 (Pralsetinib) Featured | BLU-667 (Pralsetinib) is a highly potent, selective, next generation RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion. |
|
| DC12650 | BLU-667 trans form | BLU-667 trans form is the trans form of BLU-667, which is a highly potent, selective, next generation RET inhibitor.. |
|
| DC11152 | BLU-782 Featured | BLU-782 (BLU782) is a novel potent, selective inhibitor of Activin receptor-like kinase (ALK2) mutant R206H with binding IC50 of <10 Nm. |
|
| DC8280 | BLU-9931 Featured | BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM). |
|
| DC8103 | BLZ-945 Featured | BLZ945 is a highly selective and brain-penetrant inhibitor of CSF1R with IC50 of 1 nM; >3200-fold higher than its affinity for other kinases. |
|
| DC23305 | BM-1197 | BM-1197 is a potent, specific dual inhibitor of Bcl-2 and Bcl-xL with Ki of <1 nM, shows >1,000-fold selectivity over Mcl-1. |
|
| DC9853 | BM212 Featured | BM-212 is a potent antimycobacterial agent and MmpL3 inhibitor. |
|
| DC20802 | BM-635 | BM-635 is a small molecule anti-mycobacterial compound acting by inhibiting the mycobacterial membrane protein Large 3 (MmpL3). |
|
| DC23304 | BM-957 | BM-957 is a highly potent, dual Bcl-2 and Bcl-xL inhibitor with Ki of <1 nM for both, IC50 of 5.4 and 6.0 nM, respectively. |
|
| DC7959 | BMH-21 Featured | BMH-21 is a small molecule DNA intercalator that binds ribosomal DNA and inhibits RNA polymerase I transcription; does not cause phosphorylation of H2AX. |
|
| DC7840 | BML-190 Featured | BML-190 is an indomethacin morpholinylamide which functions as a selective inverse agonist of the human cannabinoid CB2 receptor. |
|
| DC8660 | BML-210(CAY10433) Featured | BML-210 is the novel HDAC inhibitor, and its mechanism of action has not been characterized. |
|
| DC8270 | BML-277 Featured | BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM. |
|
| DC9951 | AMBMP Featured | AMBMP hydrochloride is a Wnt canonical signaling activator. Also inhibits tubulin polymerization. Suppresses TLR2/4/5-induced inflammatory response in human monocytes. Inhibits cell proliferation and induces cell cycle arrest in MDA-MB-231 breast cancer c |
|
| DC20321 | Bm-MPK1-IN-15b | Bm-MPK1-IN-15b is a potent, orally bioavailable inhibitor of B. malayi stress-activated kinase Bm-MPK1 with IC50 of 24 nM. |
|
| DC8453 | Talazoparib（BMN-673）tosylate Featured | Talazoparib, also known as BMN-673 and MDV-3800, is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity (PARP1 IC50 = 0.57 nmol/L). Talazoparib acts as an inhibitor of poly ADP ribose polymerase(PARP) which aids in single strand DNA repair. Cells that have BRCA1/2 mutations are susceptible to the cytotoxic effects of PARP inhibitors because of an accumulation of DNA damage. Talazoparib is theorized to have a higher potency than olaparib due to the additional mechanism of action called PARP trapping. PARP trapping is the mechanism of action where the PARP molecule is trapped on the DNA, which interferes with the cells ability to replicate. Talazoparib is found to be ~100 fold more efficient in PARP trapping than olaparib. |
|
| DC2008 | Talazoparib(BMN-673) Featured | BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM. |
|
| DC8452 | BMN-673 8R,9S | BMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673. BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM(PARP1). It does not inhibit PARG and is highly sensitive to PTEN mutation. |
|
| DC23833 | SB 4 (Eticovo) Featured | BMP signaling agonist sb4 is a small molecule BMP signaling agonist with EC50 of 73.6 nM, enhances the efficacy of BMPs and activates endogenous BMP4 target genes. |
|
| DC20812 | BMS 695735 | BMS 695735 is a potent, selective IGF-1R inhibitor with IC50 of 34 nM. |
|
| DC11761 | BMS-816336 | A novel potent, selective, orally active human 11β-HSD1 inhibitor with IC50 of 3.0 nM. |
|
| DC22988 | BMS-189453 Featured | BMS-189453 (BMS189453, BMS453) is a synthetic retinoid that acts as an agonist of RARβ and an antagonist of RARα and RARγ. |
|
| DC8515 | BMS-2 | BMS-2 is a potent MET kinase inhibitor with an IC50 value of 1.8nM. It also possesses potent inhibitory activity against Flt-3 and VEGFR-2 kinases, IC50 values of 4nM and 27nM respectively. |
|
| DC22032 | BMS-211 | BMS-211 is a prodrug of the parent pan-CK2 inhibitor BMS-699.. |
|
| DC11294 | BMS-212 | BMS-212 is a potent and selective stimulator of glucokinase (GK) (EC50 = 35 nM) that is promisingly used as an antidiabetic. |
|
| DC10200 | BMS-214662 | BMS-214662 is a potent and selective farnesyl transferase inhibitor with potent antitumor activity with an IC50 of 1.35 nM. |
|
| DC8762 | BMS-265246 | BMS-265246 is a potent and selective CDK1/2 inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively. |
|
| DC8513 | BMS-3 Featured | BMS-3 is a potent inhibitor of the LIM kinase. It has IC50's of 5nM and 6 nM for LIMK1 and LIMK2 respectively. |
|
| DC7375 | BMS-303141 Featured | BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor with IC50 value of 0.13 uM (human recombinant ACL). |
|
| DC8457 | BMS-309403 Featured | BMS309403 is orally active, reducing atherosclerosis in mice lacking apoplipoprotein E. |
|
